SHANGHAI–()–EpimAb Biotherapeutics, a scientific stage biotech firm specializing in bispecific antibodies, right now introduced the appointment of Jerry Su, Ph.D. because the Chief Know-how Officer of EpimAb. Dr. Su joined EpimAb in December 2019 as Senior VP, CMC and led the completion of EpimAb’s early CMC growth facility in Suzhou BioBay. On this newly created function, Dr. Su will proceed to supervise the corporate’s CMC growth and manufacturing operations.

Since he joined EpimAb, Jerry contributed considerably to the organizational development of EpimAb by efficiently finishing our absolutely practical CMC growth and manufacturing facility in Suzhou BioBay forward of plan,” stated Dr. Chengbin Wu, founder and CEO of EpimAb Biotherapeutics. “We’re delighted to advertise Jerry to this new function and look ahead to his continued contribution and management in driving manufacturing technique as we quickly advance our pipeline of novel bispecific antibodies.”

I’m honored to serve on this new function alongside the great crew of scientists and business leaders to scale EpimAb’s efforts in driving bispecifics innovation in China and worldwide,” stated Dr. Su. “With three belongings in scientific growth and a number of preclinical packages to return, environment friendly R&D and manufacturing operations in addition to regulatory methods are extra vital than ever earlier than. I’m excited to guide our efforts in a few of these key areas and execute on the potential of our bispecific platform applied sciences to drive worth for companions and sufferers.”

Dr. Su brings to EpimAb over 20 years of technical and management expertise in pharmaceutical R&D, manufacturing, and CMC operations with international and China pharmaceutical corporations, together with Pfizer, Genzyme, Merck, and Hengrui, in addition to CDMO Wuxi Biologics. Earlier than becoming a member of EpimAb, he was CEO of Zhejiang Huahai Biopharmaceuticals Co. in Hangzhou. Dr. Su has broad expertise in cell tradition, course of growth, expertise switch, validation, manufacturing and compliance operations, with robust hands-on regulatory expertise in new drug license submission in addition to post-approval product assist coping with regulatory inspection, response preparation and alter administration. Dr. Su obtained a Ph.D. in chemical engineering with a minor in statistics from West Virginia College, an M.S. in biochemical engineering from Beijing College of Chemical Know-how, and a B.S. in chemical engineering from Tianjin College.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D firm with analysis and manufacturing services in Shanghai and Suzhou, China. Based mostly on a proprietary distinctive and environment friendly bispecific antibody expertise referred to as FIT-Ig® (Fabs-In-Tandem Immunoglobulin), EpimAb is making a pipeline of its personal novel bispecific antibody therapeutics centered round immuno-oncology and different areas of excessive worth to sufferers. EpimAb can also be dedicated to diversifying its pipeline by means of selective licensing of its platform and pipeline belongings to companions worldwide. For additional info, please go to www.epimab.com



Source link